VivoSeq
Hematology

Warm Autoimmune Hemolytic Anemia

12

Pipeline Programs↗

5

Active Trials↗

9

Companies Involved↗

Warm Autoimmune Hemolytic Anemia is an emerging landscape with 12 programs across 9 companies. The most active players are AstraZeneca, Incyte, Zenas BioPharma (USA), LLC. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

0/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2Incyte logo

Incyte

1 program

Phase 3Z

Zenas BioPharma (USA), LLC

1 program

Phase 3M

Momenta Pharmaceuticals, Inc.

1 program

Phase 3G

Genzyme, a Sanofi Company

1 program

Phase 3Novartis logo

Novartis

3 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

6 of 10 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody440%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 77% of 13 pipeline programs.

Analysis

Trial Status

12

clinical trials

Terminated4 · 33%
Active, not recruiting4 · 33%
Withdrawn2 · 17%
Recruiting1 · 8%
Temporarily not available1 · 8%

Clinical Trials

Trial Activity

12 trials

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Recruiting·Sanofi logoSanofi·Phase 3·NCT07086976·90 enrolled
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT05648968·90 enrolled
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
Active, not recruiting·ZZenas BioPharma (USA), LLC·Phase 3·NCT05786573·134 enrolled
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
Active, not recruiting·Sanofi logoSanofi·Phase 2·NCT05002777·22 enrolled
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Preclinical·NCT04119050·118 enrolled
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)
Terminated·Sanofi logoSanofi·Phase 2·NCT04661033·8 enrolled
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
Terminated·IImmunovant Sciences GmbH·Phase 2·NCT04253236·5 enrolled
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia
Terminated·Incyte logoIncyte·Phase 3·NCT05073458·13 enrolled
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
Terminated·AstraZeneca logoAstraZeneca·Phase 1/2·NCT03075878·8 enrolled
ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
Withdrawn·AstraZeneca logoAstraZeneca·Phase 2·NCT04256148
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
Withdrawn·AstraZeneca logoAstraZeneca·Phase 2·NCT04956276
Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
Temporarily not available·Johnson & Johnson logoJohnson & Johnson·N/A·NCT05221619

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)